Altimmune, Inc. — Director's Dealing 2022

Jul 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-07-01

Reporting Person: Roberts M Scot (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-01	Common Stock, par value $0.0001	M	4019	$2.60	Acquired	21719	Direct
2022-07-01	Common Stock, par value $0.0001	M	22963	$2.95	Acquired	44682	Direct
2022-07-01	Common Stock, par value $0.0001	S	26982	$12.00	Disposed	17700	Direct
2022-07-05	Common Stock, par value $0.0001	M	787	$2.95	Acquired	18487	Direct
2022-07-05	Common Stock, par value $0.0001	S	10182	$12.00	Disposed	8305	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-01	Stock Options (option to buy)	$2.60	M	4019	Disposed	2029-01-02	Common Stock, par value $0.0001 (4019)	Direct
2022-07-01	Stock Options (option to buy)	$2.95	M	22963	Disposed	2029-03-26	Common Stock, par value $0.0001 (22963)	Direct
2022-07-05	Stock Options (option to buy)	$2.95	M	787	Disposed	2029-03-26	Common Stock, par value $0.0001 (787)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	15	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.